BRIEF published on 05/08/2026 at 22:35, 1 month 18 days ago Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
PRESS RELEASE published on 05/08/2026 at 22:30, 1 month 18 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRIEF published on 02/11/2026 at 22:35, 4 months 15 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 4 months 15 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 7 months 16 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 7 months 16 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 9 months 3 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 9 months 3 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 1 year 1 month ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 1 year 1 month ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
Published on 06/27/2026 at 00:00, 2 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 hour 2 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 hour 12 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 1 hour 47 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/26/2026 at 23:36, 26 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 26 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 34 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 19:50, 4 hours 11 minutes ago Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live
Published on 06/26/2026 at 07:00, 17 hours 2 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 07:30, 1 day 16 hours ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
